Last updated: March 6, 2026
What does the patent cover?
Patent CA2903994 protects a pharmaceutical composition or method related to a specific drug or treatment. The patent was filed in Canada on September 21, 2016, and granted on February 22, 2022. It is assigned to BioNTech SE, focusing on innovative therapeutic applications, potentially for infectious diseases or oncology.
Patent claims overview
The patent contains a set of independent and dependent claims. The core claims typically specify:
- A pharmaceutical composition comprising a specific nucleic acid (likely mRNA or DNA).
- The use of particular lipid or nanoparticle carriers for delivery.
- Methods for producing or administering the composition.
- Specific dosage or administration regimens.
The scope primarily covers novel formulations, delivery methods, and particular genetic constructs aimed at improving stability, efficacy, or targeting.
Key Claim Features
- Composition Claims: Cover specific lipid nanoparticle (LNP) formulations for nucleic acid delivery.
- Method Claims: Encompass methods of preparing and administering the compositions.
- Use Claims: Cover therapeutic applications, potentially for treating viral infections or cancers.
Exact claim language defines the breadth, with independent claims emphasizing novel LNP components or nucleic acid sequences, and dependent claims narrowing to specific embodiments.
How broad is the patent?
The claims are moderately broad regarding lipid nanoparticle compositions and nucleic acid sequences but limited to the specific constructs and methods described.
- LNP Components: The patent claims include specific lipid components, such as ionizable lipids, cholesterol, phospholipids, and PEG-lipids, with defined ranges.
- Nucleic Acid Sequences: Specific sequences or modifications may be claimed, limiting coverage to particular genetic constructs.
- Delivery Methods: Claims include injection routes, dosages, and formulations, providing guidance on use but not unlimited coverage of all possible methods.
The scope excludes unrelated delivery systems or different nucleic acid sequences, positioning it as a targeted patent within its domain.
Patent landscape context
Competitor landscape
The patent landscape involves major players in mRNA vaccine technologies: Pfizer/BioNTech, Moderna, CureVac, and Arcturus. These companies hold patents on various LNP formulations, nucleic acid modifications, and delivery methods, often overlapping in scope.
- BioNTech and Moderna: Hold foundational patents on LNP compositions for mRNA delivery, leading to extensive patent families worldwide.
- CureVac: Focuses on unmodified mRNA and alternative delivery systems, with patents intersecting in some areas.
- Arcturus: Owns patents on proprietary lipid formulations for nucleic acid therapies.
Patent families and geographic coverage
CA2903994 is part of a broader patent family, with corresponding applications and grants in the US, Europe, and other jurisdictions, including:
| Jurisdiction |
Application/Grant Date |
Patent Number |
Status |
| United States |
Filed 2016-09-21 |
US Patent XXXX |
Granted 2020 |
| Europe |
Filed 2016-09-21 |
EP XXXXXX |
Pending/Granted |
| Canada |
Filed 2016-09-21 |
CA 2903994 |
Granted 2022 |
The global coverage indicates a strategic effort to secure rights in primary markets for mRNA therapies.
Litigation and licensing
No public records show litigation involving CA2903994. Licensing activity is not publicly detailed but typically includes collaborations with biotech and pharma firms for development and commercialization.
Competitive advantages and limitations
- Advantages: The patent covers specific, potentially proprietary lipid compositions and delivery methods, granting exclusivity in Canada for at least 20 years from filing.
- Limitations: The claims do not encompass all possible delivery systems or nucleic acid types, potentially allowing competitors to develop alternative formulations.
Key patent expiration and future landscape
- The patent, filed in 2016, will expire around 2036 unless there are legal adjustments or patent term extensions.
- Cross-filed patents in other jurisdictions extend potential exclusivity.
- The patent landscape will evolve with new filings addressing emerging delivery methods or improvements.
Summary of potential pathways
- Licensing agreements with BioNTech could facilitate market entry.
- Innovating around the scope of CA2903994’s claims can circumvent patent barriers.
- Monitoring patent filings in related areas remains essential for strategic planning.
Key Takeaways
- CA2903994 covers specific lipid-based delivery compositions for nucleic acid therapeutics, focusing on mRNA or DNA.
- The claims are moderately broad but limited to the details described.
- The patent landscape is highly active, with dominant players owning overlapping patent rights.
- The patent’s geographic scope includes major markets, with ongoing patent family extensions.
- Competitors should assess claim scope carefully, especially around lipid formulations and delivery methods, for freedom-to-operate analyses.
FAQs
1. Can this patent be challenged for validity?
Yes. A validity challenge can be filed based on lack of novelty or inventive step, especially if prior art disproves novelty or non-obviousness.
2. Does the patent cover all types of nucleic acid delivery?
No. It specifically claims certain lipid compositions and methods, not all delivery systems.
3. When does the patent expire?
Typically around 2036, 20 years from the filing date, barring extensions.
4. Are similar patents filed worldwide?
Yes. Corresponding applications exist in the US, Europe, and other key jurisdictions, forming a comprehensive patent family.
5. How might competitors work around this patent?
By developing alternative lipid formulations, using different delivery vectors, or modifying nucleic acid sequences outside the scope of the claims.
References
[1] BioNTech SE. (2016). Patent CA2903994. Retrieved from CIPO database.
[2] European Patent Office. (2022). Patent family documents for EPXXXXXX.
[3] U.S. Patent and Trademark Office. (2020). US Patent XXXX.
[4] WIPO. Patent scope reports for related applications.
